WallStSmart
RCUS

Arcus Biosciences Inc

NYSE: RCUS · HEALTHCARE · BIOTECHNOLOGY

$24.13
-2.70% today

Updated 2026-04-29

Market cap
$3.03B
P/E ratio
P/S ratio
12.27x
EPS (TTM)
$-3.29
Dividend yield
52W range
$7 – $29
Volume
1.3M

Arcus Biosciences Inc (RCUS) Financial statements

SEC filings — annual and quarterly data.

Income statement — annual

Item2016201720182019202020212022202320242025
Revenue$0.00$1.41M$8.35M$15.00M$78.00M$383.00M$112.00M$117.00M$258.00M$247.00M
Revenue growth (YoY)+491.2%+79.6%+420.0%+391.0%-70.8%+4.5%+120.5%-4.3%
Cost of revenue$1.31M$2.61M$49.65M$78.48M$159.00M$7.06M$14.00M$340.00M$10.00M$10.00M
Gross profit$-1.31M$1.41M$8.35M$15.00M$78.00M$383.00M$112.00M$117.00M$258.00M$237.00M
Gross margin100.0%100.0%100.0%100.0%100.0%100.0%100.0%100.0%96.0%
R&D$14.25M$47.22M$49.65M$78.48M$159.00M$257.00M$288.00M$340.00M$448.00M$523.00M
SG&A$3.94M$7.64M$13.57M$25.23M$43.00M$72.00M$104.00M$117.00M$120.00M$110.00M
Operating income$-18.18M$-53.44M$-54.86M$-88.71M$-124.00M$54.00M$-280.00M$-340.00M$-330.00M$-386.00M
Operating margin-3782.1%-656.8%-591.4%-159.0%14.1%-250.0%-290.6%-127.9%-156.3%
EBITDA$-16.87M$-50.83M$-51.20M$-85.13M$-120.00M$59.00M$-258.00M$-291.00M$-269.00M$-335.00M
EBITDA margin-3597.2%-612.9%-567.5%-153.8%15.4%-230.4%-248.7%-104.3%-135.6%
EBIT$-18.18M$-53.44M$-54.86M$-88.71M$-123.00M$55.00M$-264.00M$-299.00M$-279.00M$-345.00M
Interest expense$0.00$0.00$4.92M$0.00$0.00$260000.00$2.00M$2.00M$4.00M$8.00M
Income tax
Effective tax rate0.0%0.0%0.0%0.0%0.0%0.0%0.0%0.0%0.0%0.0%
Net income$-17.97M$-53.08M$-49.59M$-75.93M$-123.00M$53.00M$-267.00M$-307.00M$-283.00M$-353.00M
Net income growth (YoY)-195.4%+6.6%-53.1%-62.0%+143.1%-603.8%-15.0%+7.8%-24.7%
Profit margin-3756.7%-593.7%-506.2%-157.7%13.8%-238.4%-262.4%-109.7%-142.9%